BR9408265A - C5a receptor antagonists having substantially no antagonist activity - Google Patents

C5a receptor antagonists having substantially no antagonist activity

Info

Publication number
BR9408265A
BR9408265A BR9408265A BR9408265A BR9408265A BR 9408265 A BR9408265 A BR 9408265A BR 9408265 A BR9408265 A BR 9408265A BR 9408265 A BR9408265 A BR 9408265A BR 9408265 A BR9408265 A BR 9408265A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
antagonist activity
antagonist
activity
antagonists
Prior art date
Application number
BR9408265A
Other languages
Portuguese (pt)
Inventor
Jan Van Oostrum
William C Boyar
Nicholas G Galakatos
Jane V Peppard
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of BR9408265A publication Critical patent/BR9408265A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
BR9408265A 1993-12-06 1994-11-16 C5a receptor antagonists having substantially no antagonist activity BR9408265A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16259193A 1993-12-06 1993-12-06
PCT/IB1994/000359 WO1995016033A1 (en) 1993-12-06 1994-11-16 C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY

Publications (1)

Publication Number Publication Date
BR9408265A true BR9408265A (en) 1996-12-10

Family

ID=22586301

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9408265A BR9408265A (en) 1993-12-06 1994-11-16 C5a receptor antagonists having substantially no antagonist activity

Country Status (15)

Country Link
EP (1) EP0733107A1 (en)
JP (1) JPH09506258A (en)
CN (1) CN1142854A (en)
AU (1) AU698919B2 (en)
BR (1) BR9408265A (en)
CA (1) CA2176825A1 (en)
FI (1) FI962319A0 (en)
HU (1) HUT75990A (en)
IL (1) IL111792A0 (en)
MX (1) MXPA99008669A (en)
NO (1) NO962348L (en)
NZ (1) NZ274917A (en)
TW (1) TW429262B (en)
WO (1) WO1995016033A1 (en)
ZA (1) ZA949647B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
WO1996039503A1 (en) * 1995-06-05 1996-12-12 Novartis Ag C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY AND METHODS FOR PREPARATION
BR9607139A (en) * 1995-12-13 1997-11-25 Northern Telecom Ltd Data telecommunications systems with digital package and integrated cellular voice and processes for their operation
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
TWI767415B (en) * 2020-11-18 2022-06-11 中國醫藥大學 Automatic blood analysis system and automatic blood analysis method
CN113150106B (en) * 2021-04-26 2022-08-16 华中农业大学 Antibacterial peptide derived from complement component C5a and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305615A1 (en) * 1987-09-03 1989-03-08 Immunetech Pharmaceuticals, Inc. Peptide antagonists for the C5a anaphylatoxin
JP2703764B2 (en) * 1986-04-28 1998-01-26 シータス オンコロジー コーポレイション Monoclonal antibody against complement component C5a

Also Published As

Publication number Publication date
TW429262B (en) 2001-04-11
NO962348L (en) 1996-08-05
IL111792A0 (en) 1995-01-24
CN1142854A (en) 1997-02-12
FI962319A (en) 1996-06-03
WO1995016033A1 (en) 1995-06-15
AU698919B2 (en) 1998-11-12
EP0733107A1 (en) 1996-09-25
CA2176825A1 (en) 1995-06-15
HU9601538D0 (en) 1996-07-29
MXPA99008669A (en) 2004-09-01
AU8002594A (en) 1995-06-27
FI962319A0 (en) 1996-06-03
JPH09506258A (en) 1997-06-24
HUT75990A (en) 1997-05-28
NO962348D0 (en) 1996-06-05
NZ274917A (en) 1998-03-25
ZA949647B (en) 1995-06-06

Similar Documents

Publication Publication Date Title
BR9508178A (en) Vitronectin receptor antagonists
BR9712248A (en) Vitronectin receptor antagonist
BR9612327A (en) Vitronectin receptor antagonists
BR9612378A (en) Vitronectin receptor antagonists
BR9612381A (en) Vitronectin receptor antagonists
NO972016D0 (en) Indolyl-Y receptor antagonists
BR9407933A (en) Endothelin receptor antagonists
NO983737D0 (en) IL-8 receptor antagonists
ZA955391B (en) Vitronectin receptor antagonists
BR9206722A (en) Endothelin receptor antagonist
MX9101311A (en) FIBRINOGEN RECEPTOR ANTAGONISTS
NO993350D0 (en) Vitronectin receptor antagonists
ID16742A (en) ENDOTELIN RECEPTOR ANTAGONISTS
DE69429861T2 (en) Endothelin receptor Antagonist
NO20001514D0 (en) Vitronectin receptor antagonist
NO20001515D0 (en) Vitronectin receptor antagonist
NO20001407D0 (en) Vitronectin receptor antagonists
BR9507220A (en) Endothelin receptor antagonists
DZ2322A1 (en) Vitronectin receptor antagonists.
NO179550C (en) Tachykinin receptor antagonists
BR9408265A (en) C5a receptor antagonists having substantially no antagonist activity
ZA968939B (en) Fibrinogen receptor antagonist
LV10425A (en) Fibrinogen receptor antagonists

Legal Events

Date Code Title Description
PC Transfer

Free format text: NOVARTIS AG (NOVARTIS SA) (NOVARTIS INC.) (CH)

EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
CKFC Appeal: appeal against refusal
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]